tiprankstipranks
Advertisement

SLYG - ETF AI Analysis

Compare

Top Page

SLYG

SPDR S&P 600 Small Cap Growth ETF (SLYG)

Rating:69Neutral
Price Target:
SLYG, the SPDR S&P 600 Small Cap Growth ETF, has a solid overall rating driven largely by strong holdings like Krystal Biotech and Alkermes, which benefit from robust financial performance, strategic growth initiatives, and positive earnings call sentiment. Argan also supports the fund’s quality with a healthy backlog and growth focus, while weaker names such as ViaSat and StoneX Group, which face profitability and leverage challenges, modestly weigh on the rating. The main risk factor is the fund’s exposure to smaller growth companies, where high valuations, leverage, and occasional overbought technical conditions can lead to sharper price swings.
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year, showing solid momentum in its small-cap growth strategy.
Leading Holdings Performing Well
Several of the top positions, especially in health care and technology, have shown strong price performance, helping drive the fund’s returns.
Low Expense Ratio
The fund’s relatively low fee means more of the investment returns stay in investors’ pockets compared with many actively managed alternatives.
Negative Factors
High U.S. Concentration
With almost all assets in U.S. companies, the ETF offers little geographic diversification and is heavily tied to the U.S. economy.
Small-Cap Volatility
Because it focuses on smaller growth companies, the fund can be more sensitive to market swings and economic slowdowns than large-cap funds.
Sector Tilts Toward Cyclical Areas
Significant exposure to sectors like industrials, technology, and consumer cyclical means the ETF may be more affected by changes in business cycles and investor risk appetite.

SLYG vs. SPDR S&P 500 ETF (SPY)

SLYG Summary

SLYG is the SPDR S&P 600 Small Cap Growth ETF, which follows the S&P SmallCap 600 Growth Index. It invests in many smaller U.S. companies that are trying to grow quickly, across areas like technology, health care, and industrials. Some of its holdings include ViaSat and Brinker International. An investor might choose SLYG to add growth potential and diversification from large, well-known stocks, since it spreads money across many smaller firms. However, small-cap growth stocks can be more volatile, so the ETF’s price can move up and down more sharply than the overall market.
How much will it cost me?The SPDR S&P 600 Small Cap Growth ETF (SLYG) has an expense ratio of 0.15%, meaning you’ll pay $1.50 per year for every $1,000 invested. This is lower than average for ETFs because it is passively managed, tracking the S&P SmallCap 600 Growth Index rather than relying on active stock picking.
What would affect this ETF?SLYG could benefit from a strong U.S. economy, as its focus on small-cap growth companies in sectors like Industrials and Technology aligns with innovation and infrastructure trends. However, rising interest rates or economic slowdowns may negatively impact small-cap stocks, which are often more sensitive to borrowing costs and market volatility. Regulatory changes or sector-specific challenges in areas like Health Care or Financials could also influence the ETF's performance.

SLYG Top 10 Holdings

SLYG leans into U.S. small-cap growth, with health care and tech names doing much of the heavy lifting. Corcept Therapeutics and Protagonist Therapeutics have been rising steadily, giving the fund a strong biotech flavor, while ViaSat’s momentum adds a tech-driven tailwind. On the flip side, FormFactor and Argan have seen more mixed, recently lagging action, occasionally acting as speed bumps for performance. Overall, the ETF is a domestically focused, small-cap growth story, powered by innovative health care and technology players with a few industrials in the mix.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
ViaSat1.14%$58.16M$10.21B352.26%
56
Neutral
Corcept Therapeutics1.02%$52.00M$10.11B32.96%
76
Outperform
Ryman0.97%$49.59M$8.58B39.94%
66
Neutral
Brinker International0.97%$49.13M$8.50B24.02%
70
Neutral
Alkermes0.96%$48.63M$8.42B73.08%
80
Outperform
Protagonist Therapeutics0.94%$47.80M$8.80B143.50%
68
Neutral
Etsy0.93%$47.43M$8.21B38.08%
57
Neutral
Esco Technologies0.93%$47.26M$8.18B53.56%
70
Neutral
StoneX Group0.89%$45.42M$8.83B65.81%
58
Neutral
Armstrong World0.87%$44.07M$7.62B-8.16%
77
Outperform

SLYG Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price
Price Trends
50DMA
112.93
Positive
100DMA
107.38
Positive
200DMA
101.94
Positive
Market Momentum
MACD
RSI
STOCH
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SLYG, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 115.78, equal to the 50-day MA of 112.93, and equal to the 200-day MA of 101.94, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SLYG.

SLYG Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$5.09B0.15%
69
Neutral
$9.20B0.25%
67
Neutral
$8.24B0.18%
68
Neutral
$1.49B0.06%
60
Neutral
$1.28B0.70%
63
Neutral
$1.10B0.10%
68
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SLYG
SPDR S&P 600 Small Cap Growth ETF
115.52
27.01
30.52%
FNDA
Schwab Fundamental US Small Co. Index ETF
IJT
iShares S&P Small-Cap 600 Growth ETF
VTWG
Vanguard Russell 2000 Growth ETF
FYC
First Trust Small Cap Growth AlphaDEX Fund
VIOG
Vanguard S&P Small-Cap 600 Growth ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement